| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 3348626 | Diagnostic Microbiology and Infectious Disease | 2008 | 4 Pages |
Abstract
Twenty-three generic intravenous piperacillin/tazobactam products were compared for in vitro activity to the branded formulation (Zosyn®, Wyeth, Philadelphia, PA) by disk diffusion and incremental broth microdilution assay methods. All but 1 lot demonstrated significantly decreased activity (−5 to −35%), necessitating further investigations regarding the chemical purity, potency, and therapeutic equivalence of these products worldwide. The average −16% activity across all generic lots was equivalent to underdosing piperacillin/tazobactam by 2.6 g daily for serious clinical infections (4.5 g Q6 h).
Keywords
Related Topics
Life Sciences
Immunology and Microbiology
Applied Microbiology and Biotechnology
Authors
Ronald N. Jones, Thomas R. Fritsche, Gary J. Moet,